Ad is loading...
MENU

PLRX Stock Pliant Therapeutics (PLRX, $14.63) RSI Indicator left the overbought zone on December 03, 2024

A.I.dvisor
at Tickeron.com
Loading...
PLRX - Pliant Therapeutics
RSI signal
Bearish Trend
Odds of DOWN Trend
Tickeron
RSI signal
Price: $14.63
Daily change: -$0.88 (-5.67%)
Daily volume: 592.2K
Capitalization: $890.3M
Industry: Biotechnology
This is a signal that PLRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 24 similar cases where PLRX's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:

PLRX sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for PLRX moved above the 200-day moving average on December 03, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 29, 2024. You may want to consider a long position or call options on PLRX as a result. In of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PLRX just turned positive on December 02, 2024. Looking at past instances where PLRX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

PLRX moved above its 50-day moving average on November 25, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PLRX crossed bullishly above the 50-day moving average on December 02, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PLRX advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 94 cases where PLRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PLRX moved out of overbought territory on December 03, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 43 cases where PLRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PLRX broke above its upper Bollinger Band on December 02, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PLRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.513) is normal, around the industry mean (14.155). P/E Ratio (0.000) is within average values for comparable stocks, (88.146). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). PLRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). PLRX's P/S Ratio (3333.333) is very high in comparison to the industry average of (226.159).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
PLRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in the business of developing and commercializing novel therapies for fibrotic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
260 Littlefield Avenue
Phone
+1 650 481-6770
Employees
158
Web
https://www.pliantrx.com